Evaluation of the association between bevacizumab concentration and clinical outcomes in patients with breast cancer brain metastasis
Open Access
Abstract
No abstract availableKeywords
Funding Information
- National Taiwan University (NSTC 110-2113-M-002 -006 -MY3)
- Ministry of Education
- National Science and Technology Council (110-2113-M-002 -006 -MY3)
This publication has 31 references indexed in Scilit:
- Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast CancerJAMA Oncology, 2024
- Population pharmacokinetics and exposure–response relationship of trastuzumab and bevacizumab in early-stage breast cancerEuropean Journal of Clinical Pharmacology, 2021
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- Correlation Between Bevacizumab Exposure and Survival Does Not Necessarily Imply CausalityThe Oncologist, 2020
- Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survivalJournal of Neuro-Oncology, 2020
- Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS MalignanciesDrugs in R&D, 2017
- The role of bevacizumab in the treatment of glioblastomaJournal of Neuro-Oncology, 2017
- Population pharmacokinetics of bevacizumab in cancer patients with external validationCancer Chemotherapy and Pharmacology, 2016
- Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer PatientsClinical Pharmacokinetics, 2016
- Proposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage formsBiopharmaceutics & Drug Disposition, 2014